Search Within

Alexandra Elizabeth Snyder Charen

Refine Results
Formats
  1. Journal Article (41)
  2. Meeting Abstract (13)
  3. Book Section (1)
Groups
  1. Solid Tumor Oncology Division (50)
  2. GSK Faculty (31)
  3. Human Oncology and Pathogenesis Program (22)
  4. Melanoma and Immunotherapeutics Service (22)
  5. Gynecologic Medicine Service (19)
  6. Genitourinary Oncology Service (16)

More Groups

People
  1. Jedd Wolchok (19)
  2. Matthew Hellmann (13)
  3. Taha Merghoub (13)
  4. Timothy Chan (13)
  5. Dmitriy Zamarin (10)
  6. Carol Aghajanian (8)

More People

Years
  1. 2020 (1)
  2. 2019 (3)
  3. 2018 (10)
  4. 2017 (14)
  5. 2016 (9)
  6. 2015 (12)

More Years

Publications
  1. Journal of Clinical Oncology (10)
  2. Science (4)
  3. Annals of Oncology (3)
  4. Cancer Immunology Research (3)
  5. Cell (3)
  6. New England Journal of Medicine (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (12)
  2. American Association for Cancer Research (7)
  3. Cell Press (6)
  4. Nature Publishing Group (5)
  5. American Association for the Advancement of Science (4)
  6. Elsevier Inc. (4)

More Publishers

Results (55)

Export to EndNote | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy
    Journal Article

    Jiménez-Sánchez, A.; Cybulska, P.; LaVigne Mager, K.; Koplev, S.; Cast, O.; Couturier, D. L.; Memon, D.; Selenica, P.; Nikolovski, I.; Mazaheri, Y.; more...
    Nature Genetics (2020)

    Fulltext@MSK | Save
  • Radiogenomics analysis of intratumor heterogeneity in a patient with high-grade serous ovarian cancer
    Journal Article

    Weigelt, B.; Vargas, H. A.; Selenica, P.; Geyer, F. C.; Mazaheri, Y.; Blecua, P.; Conlon, N.; Hoang, L. N.; Jungbluth, A. A.; Snyder, A.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • TOX is a critical regulator of tumour-specific T cell differentiation
    Journal Article

    Scott, A. C.; Dündar, F.; Zumbo, P.; Chandran, S. S.; Klebanoff, C. A.; Shakiba, M.; Trivedi, P.; Menocal, L.; Appleby, H.; Camara, S.; more...
    Nature (2019)

    Fulltext@MSK | Save
  • Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
    Journal Article

    Boland, J. L.; Zhou, Q.; Martin, M.; Callahan, M. K.; Konner, J.; O'Cearbhaill, R. E.; Friedman, C. F.; Tew, W.; Makker, V.; Grisham, R. N.; more...
    Gynecologic Oncology (2019)

    Fulltext@MSK | Save
  • Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC)
    Meeting Abstract

    Voss, M. H.; Novik, J. B.; Hellmann, M. D.; Ball, M.; Hakimi, A. A.; Miao, D.; Margolis, C.; Horak, C.; Wind-Rotolo, M.; De Velasco, G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Checkpoint blockade
    Book Section

    Proverbs-Singh, T. A.; Wolchok, J.; Snyder, A.
    In Cooper, L. J. N.; Mittendorf, E. A.; Moyes, J.; Prabhakaran, S. (Eds.) Immunotherapy in Translational Cancer Research (2018)

    Fulltext@MSK | Save
  • A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor
    Journal Article

    Leiserson, M. D. M.; Syrgkanis, V.; Gilson, A.; Dudik, M.; Gillett, S.; Chayes, J.; Borgs, C.; Bajorin, D. F.; Rosenberg, J. E.; Funt, S.; more...
    PLoS ONE (2018)

    Fulltext@MSK | Save
  • Clinical utility of prospective molecular characterization in advanced endometrial cancer
    Journal Article

    Soumerai, T. E.; Donoghue, M. T. A.; Bandlamudi, C.; Srinivasan, P.; Chang, M. T.; Zamarin, D.; Cadoo, K. A.; Grisham, R. N.; O'Cearbhaill, R. E.; Tew, W. P.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers
    Journal Article

    Teo, M. Y.; Seier, K.; Ostrovnaya, I.; Regazzi, A. M.; Kania, B. E.; Moran, M. M.; Cipolla, C. K.; Bluth, M. J.; Chaim, J.; Al-Ahmadie, H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer
    Journal Article

    Hellmann, M. D.; Nathanson, T.; Rizvi, H.; Creelan, B. C.; Sanchez-Vega, F.; Ahuja, A.; Ni, A.; Novik, J. B.; Mangarin, L. M. B.; Abu-Akeel, M.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save